表紙
市場調査レポート

慢性心不全:現在・将来の市場参入企業

Chronic Heart Failure - Current and Future Players

発行 GlobalData 商品コード 277050
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
慢性心不全:現在・将来の市場参入企業 Chronic Heart Failure - Current and Future Players
出版日: 2013年06月30日 ページ情報: 英文 38 Pages
概要

当レポートでは、世界の慢性心不全の関連市場における既存/新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 市場予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概略
  • 企業戦略の傾向
  • 企業プロファイル
    • Novartis

第5章 付録

図表一覧

目次
Product Code: GDHC1007FPR

Summary

GlobalData has released its pharma report, "Chronic Heart Failure - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Chronic heart failure (CHF) Market. The report identifies and analyses the key companies shaping and driving the global CHF market. The report provides insight into the competitive CHF landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for CHF
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of CHF sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving CHF Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global CHF market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Novartis

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. NYHA Class Segmentation of Total Prevalent CHF Population
    • 5.4.2. Diagnosed CHF Population
    • 5.4.3. Drug-Treated CHF Population
    • 5.4.4. Patient Population Breakdown: HF-REF versus HF-PEF
    • 5.4.5. Treatment of HF-REF versus HF-PEF
    • 5.4.6. Drugs Included in Each Therapeutic Class
    • 5.4.7. Launch and Patent Expiry Dates
    • 5.4.8. General Pricing Assumptions
    • 5.4.9. Drugs Assumptions
    • 5.4.10. Generic Erosion
    • 5.4.11. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Survey of Prescribing Physicians
  • 5.7. About the Authors
    • 5.7.1. Author
    • 5.7.2. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for CHF, 2012-2022
  • Table 2: Global CHF Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the CHF Market, 2012
  • Table 4: Novartis' CHF Portfolio Assessment, 2012
  • Table 5: Novartis SWOT Analysis, 2012
  • Table 6: Key Launch or Approval Dates
  • Table 7: Key Patent Expiries
  • Table 8: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for CHF ($bn) by Region, 2012-2022
Back to Top